Search

Hengsheng Feng

from Cherry Hill, NJ
Get Report
Connected to:
Alisa J Feng, 53Chaoyi Feng, 31Chloe E Feng, 26Christina T Feng, 55Eddy Y Feng, 60Gen Feng, 47Haoqi Feng, 40Hongwei Feng, 55Huiyun Feng, 53Jan Feng, 62

Hengsheng Feng Phones & Addresses

  • 1 Forage Ln, Cherry Hill, NJ 08003 (856) 267-5037 (856) 424-2278
  • Philadelphia, PA
  • 1 Forage Ln, Cherry Hill, NJ 08003 (856) 267-5037

Work

Position: Clerical/White Collar

Education

Degree: Graduate or professional degree

Publications

Us Patents

Methods Of Use Of Fenofibric Acid

View page
US Patent:
7741373, Jun 22, 2010
Filed:
Jul 13, 2009
Appl. No.:
12/501678
Inventors:
Kristin Anne Arnold - Morrisville PA, US
Hengsheng Feng - Cherry Hill NJ, US
Assignee:
Mutual Pharmacuetical Company, Inc. - Philadelphia PA
International Classification:
A61K 31/12
US Classification:
514687
Abstract:
Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.

Methods Of Use Of Fenofibric Acid

View page
US Patent:
7741374, Jun 22, 2010
Filed:
Sep 10, 2009
Appl. No.:
12/556644
Inventors:
Kristin Anne Arnold - Morrisville PA, US
Hengsheng Feng - Cherry Hill NJ, US
Assignee:
Mutual Pharmaceutical Company, Inc. - Philadelphia PA
International Classification:
A61K 31/12
US Classification:
514687
Abstract:
Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.

Methods Of Use Of Fenofibric Acid

View page
US Patent:
7915247, Mar 29, 2011
Filed:
Jun 18, 2008
Appl. No.:
12/141280
Inventors:
Kristin Anne Arnold - Morrisville PA, US
Hengsheng Feng - Cherry Hill NJ, US
Assignee:
Mutual Pharmaceutical Company, Inc. - Philadelphia PA
International Classification:
A61K 31/30
A61K 31/12
US Classification:
514183, 514687
Abstract:
Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.

Colchicine Compositions And Methods

View page
US Patent:
8415395, Apr 9, 2013
Filed:
Apr 19, 2012
Appl. No.:
13/451328
Inventors:
Matthew W. Davis - Erwinna PA, US
Hengsheng Feng - Cherry Hill NJ, US
Assignee:
Takeda Pharmaceuticals U.S.A., Inc. - Deerfield IL
International Classification:
A01N 37/18
A61K 31/16
C07C 233/00
C07C 235/00
C07C 237/00
C07C 239/00
C07C 211/00
C07C 205/00
C07C 207/00
US Classification:
514629, 564123, 564308, 564427, 568306
Abstract:
Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.

Colchine Compositions And Methods

View page
US Patent:
8415396, Apr 9, 2013
Filed:
Apr 20, 2012
Appl. No.:
13/452277
Inventors:
Matthew W. Davis - Erwinna PA, US
Hengsheng Feng - Cherry Hill NJ, US
Assignee:
Takeda Pharmaceuticals U.S.A., Inc. - Deerfield IL
International Classification:
A01N 37/18
A61K 31/16
C07C 233/00
C07C 235/00
C07C 237/00
C07C 239/00
C07C 211/00
C07C 205/00
C07C 207/00
US Classification:
514629, 564123, 564308, 564427, 568306
Abstract:
Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.

Active Agent Formulations, Methods Of Making, And Methods Of Use

View page
US Patent:
20080050450, Feb 28, 2008
Filed:
Jun 26, 2007
Appl. No.:
11/768476
Inventors:
Kristin Arnold - Morrisville PA, US
Hengsheng Feng - Cherry Hill NJ, US
Kurt Nielsen - Chadds Ford PA, US
Assignee:
MUTUAL PHARMACEUTICAL COMPANY, INC. - Philadelphia PA
International Classification:
A61K 9/14
A61K 31/216
A61K 31/421
A61P 3/00
A61K 31/551
US Classification:
424501000, 424489000, 514212040, 514376000, 514545000
Abstract:
Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof, are also disclosed. In some embodiments, the active agent is fenofibrate. In other embodiments, the fenofibrate compositions are in a treatment form that that is bioequivalent to TriCor 145 mg or 48 mg.

Active Agent Formulations, Methods Of Making, And Methods Of Use

View page
US Patent:
20080220076, Sep 11, 2008
Filed:
May 16, 2008
Appl. No.:
12/122402
Inventors:
Kristin Anne Arnold - Morrisville PA, US
Hengsheng Feng - Cherry Hill NJ, US
Kurt R. Nielsen - Chadds Ford PA, US
Assignee:
MUTUAL PHARMACEUTICAL COMPANY, INC. - Philadelphia PA
International Classification:
A61K 9/14
A61K 31/454
A61K 31/4355
A61K 31/436
US Classification:
424489, 514323, 514291
Abstract:
Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof, are also disclosed.

Active Agent Formulations, Methods Of Making, And Methods Of Use

View page
US Patent:
20090074872, Mar 19, 2009
Filed:
Nov 20, 2008
Appl. No.:
12/274427
Inventors:
Kristin Anne Arnold - Morrisville PA, US
Hengsheng Feng - Cherry Hill NJ, US
Assignee:
MUTUAL PHARMACEUTICAL COMPANY, INC. - Philadelphia PA
International Classification:
A61K 9/16
A61K 31/216
US Classification:
424489, 514512, 977773
Abstract:
Stable fenofibrate suspensions are disclosed herein. A fenofibrate composition includes fenofibrate nanoparticles having an average particle size of less than 500 nm, and a particle sequestrant, wherein the average particle size of the nanoparticulate suspension changes by less than 50% after standing at room temperature for 21 or more days.
Control profile
Hengsheng Feng from Cherry Hill, NJ Get Report